Clinical Trial Update: Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating revascularization versus conservative treatment in heart-lung transplant rejection patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart-lung Transplant Rejection

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Heart-lung Transplant Rejection | Phase 3 | Status: TERMINATED